- Home
- HUIZ vs SCYX Comparison
HUIZ vs SCYX Comparison
Compare HUIZ & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUIZ
- SCYX
- Stock Information
- Founded
- HUIZ 2006
- SCYX 1999
- Country
- HUIZ China
- SCYX United States
- Employees
- HUIZ N/A
- SCYX N/A
- Industry
- HUIZ Specialty Insurers
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- HUIZ Finance
- SCYX Health Care
- Exchange
- HUIZ Nasdaq
- SCYX Nasdaq
- Market Cap
- HUIZ 32.8M
- SCYX 32.3M
- IPO Year
- HUIZ 2020
- SCYX 2014
- Fundamental
- Price
- HUIZ $3.95
- SCYX $0.78
- Analyst Decision
- HUIZ Hold
- SCYX
- Analyst Count
- HUIZ 1
- SCYX 0
- Target Price
- HUIZ $2.30
- SCYX N/A
- AVG Volume (30 Days)
- HUIZ 24.9K
- SCYX 697.5K
- Earning Date
- HUIZ 12-09-2025
- SCYX 11-10-2025
- Dividend Yield
- HUIZ N/A
- SCYX N/A
- EPS Growth
- HUIZ N/A
- SCYX N/A
- EPS
- HUIZ 0.25
- SCYX N/A
- Revenue
- HUIZ $186,519,166.00
- SCYX $3,257,000.00
- Revenue This Year
- HUIZ $22.67
- SCYX $20.23
- Revenue Next Year
- HUIZ $8.55
- SCYX $933.90
- P/E Ratio
- HUIZ $15.46
- SCYX N/A
- Revenue Growth
- HUIZ 19.12
- SCYX N/A
- 52 Week Low
- HUIZ $1.50
- SCYX $0.66
- 52 Week High
- HUIZ $10.58
- SCYX $1.49
- Technical
- Relative Strength Index (RSI)
- HUIZ 58.43
- SCYX 40.95
- Support Level
- HUIZ $3.31
- SCYX $0.76
- Resistance Level
- HUIZ $4.05
- SCYX $0.82
- Average True Range (ATR)
- HUIZ 0.31
- SCYX 0.06
- MACD
- HUIZ -0.02
- SCYX 0.00
- Stochastic Oscillator
- HUIZ 66.61
- SCYX 27.75
About HUIZ Huize Holding Limited
Huize Holding Ltd is an independent online insurance product and service platform in China. The company distributes on its platform insurance products underwritten by the insurance companies that cooperate with the company, which the company refers to as its insurer partners, and helps them reach a large number of insurance clients. The company's platform offers a digitalized insurance purchase experience and services through various internet and mobile internet channels. The company generates revenues from the insurance brokerage fees paid by its insurer partners.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.